Valuation: Armata Pharmaceuticals, Inc.

Market Cap 135M 121M 112M 101M 190M 12.88B 193M 1.35B 533M 6.73B 508M 497M 21.32B P/E 2026 *
-1.95x
P/E 2027 * -2.52x
Enterprise Value 135M 121M 112M 101M 190M 12.88B 193M 1.35B 533M 6.73B 508M 497M 21.32B EV / Sales 2026 *
31.8x
EV / Sales 2027 * 49.2x
Free-Float
32.36%
Yield 2026 *
-
Yield 2027 * -
1 day-3.98%
1 week+12.96%
Current month-5.50%
1 month-8.25%
3 months-32.66%
6 months-68.47%
Current year-44.78%
1 week 2.94
Extreme 2.935
3.8
1 month 2.74
Extreme 2.745
4.07
Current year 2.74
Extreme 2.745
14.98
1 year 2.74
Extreme 2.745
14.98
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 11/07/2023
Director of Finance/CFO 42 16/08/2024
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 09/05/2019
Director/Board Member 66 12/02/2020
Director/Board Member 51 12/02/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/07/26 Tax

Chief Executive Officer

-14,041 0.0382%
24/04/26 Free

Director

51,280 0.1400%
14/03/26 Tax

Public Communications Manager

1,030 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
-3.98%+12.96%-34.19%+66.73% 135M
+0.88%+1.18%+40.64%+74.91% 64.69B
-0.26%+6.91%+9.79%+77.36% 54.78B
+0.47%+3.52%+9.71%+100.95% 53.49B
-1.90%+3.44%+26.48%+49.12% 45.98B
-1.53%+0.16%+17.54%+123.55% 42.94B
-0.85%+1.05%+217.40%+824.46% 40.08B
-2.26%-2.06%+15.38%+45.14% 33.52B
+0.22%-4.77%+26.59%+0.55% 23.97B
+12.10%+16.60%+58.50%+46.15% 23.67B
Average +0.28%+2.80%+38.79%+140.89% 38.32B
Weighted average by Cap. +0.25%+2.59%+44.10%+150.60%

Financials

2026 *2027 *
Net sales 4.25M 3.8M 3.52M 3.18M 5.96M 404M 6.06M 42.31M 16.74M 211M 15.95M 15.61M 670M 2.75M 2.46M 2.28M 2.06M 3.86M 262M 3.92M 27.38M 10.83M 137M 10.32M 10.1M 433M
Net income -76.6M -68.5M -63.37M -57.38M -107M -7.29B -109M -763M -302M -3.81B -287M -281M -12.07B -72M -64.38M -59.56M -53.93M -101M -6.85B -103M -717M -284M -3.58B -270M -264M -11.34B
Net Debt - -
Projected Income Statement - Annual - Armata Pharmaceuticals, Inc.
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
26/10/26 $3.468 -4.73% 25,582
23/10/26 $3.640 +5.51% 115,590
22/10/26 $3.450 +12.75% 107,994
21/10/26 $3.060 -4.38% 93,557
20/10/26 $3.200 +4.23% 87,387
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Armata Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.640USD
Average target price
17.50USD
Spread / Average Target
+380.77%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Armata Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. ARMP Stock